What Oncolytics Biotech Inc does.

We are a clinical-stage biopharmaceutical company developing pelareorep, a well-tolerated intravenously delivered immunotherapeutic agent that selectively replicates in RAS-mutated tumors and activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments.

Pelareorep is a proprietary isolate of reovirus, a naturally occurring, non-pathogenic double-stranded RNA (“dsRNA”) virus commonly found in environmental waters. Pelareorep has shown promising results in changing the tumor microenvironment (“TME”). This creates a more immunologically favorable TME, making the tumor more susceptible to various treatment combinations. These treatments include chemotherapies, checkpoint inhibitors (“CPIs”), and other immuno-oncology approaches such as CAR T therapies, bispecific antibodies, and RAS or CDK4/6 inhibitors. Pelareorep induces a new army of tumor-reactive T cells, helps these cells to infiltrate the tumor through an inflammatory process, and upregulates the expression of PD-1/PD-L1. By priming the immune system with pelareorep, we believe we can increase the proportion of patients who respond to various cancer treatments, including immunotherapies, especially in cancers where existing treatment regimens have failed or provided limited benefit.

Revenue and profit, by fiscal year.

More on ONCY.

• Oncolytics Biotech Inc summary
• Oncolytics Biotech Inc financial statements
• Oncolytics Biotech Inc key metrics
• Oncolytics Biotech Inc health scores and style box
• Oncolytics Biotech Inc earnings
• Oncolytics Biotech Inc dividends
• Oncolytics Biotech Inc valuation
• Oncolytics Biotech Inc ownership and insiders
• Oncolytics Biotech Inc peers

Figures from Oncolytics Biotech Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.